Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A403XC | ISIN: US03835L3069 | Ticker-Symbol: AP8
Lang & Schwarz
14.11.24
07:00 Uhr
0,154 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
APTEVO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
APTEVO THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1510,15707:00

Aktuelle News zur APTEVO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAptevo Therapeutics: First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial274Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable diseaseColon...
► Artikel lesen
07.11.Aptevo Therapeutics Non-GAAP EPS of -$0.482
07.11.Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update234Company Achieves Milestones in Both Clinical ProgramsInitiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial ResultsPresented...
► Artikel lesen
07.11.Aptevo Therapeutics Inc. - 10-Q, Quarterly Report1
07.11.Aptevo Therapeutics Inc. - 8-K, Current Report1
29.10.Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024178LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / October 29, 2024 / Alligator Bioscience AB ("Alligator") (STO:ATORX)(ATORX) and Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO) today announced that new, positive...
► Artikel lesen
APTEVO THERAPEUTICS Aktie jetzt für 0€ handeln
29.10.Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024164SEATTLE WA AND LUND, SWEDEN / ACCESSWIRE / October 29, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB ("Alligator") (ATORX) today announced that new, positive interim...
► Artikel lesen
29.10.Aptevo and Alligator Bioscience to present Phase 1 trial data at SITC5
25.10.Aptevo Therapeutics erhält Zustimmung der Aktionäre für wichtige Vorschläge5
25.10.Aptevo Therapeutics secures shareholder nod for key proposals2
25.10.Aptevo Therapeutics Inc. - 8-K, Current Report1
11.10.APVO stock plunges to 52-week low of $0.14 amid market challenges1
11.10.APVO-Aktie stürzt auf 52-Wochen-Tief von 0,14 US-Dollar-
23.09.Roth/MKM senkt Kursziel für Aptevo Therapeutics, behält aber Kaufempfehlung aufgrund klinischer Studie bei4
23.09.Roth/MKM cuts Aptevo Therapeutics stock target, keeps Buy on clinical trial2
18.09.Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules292SEATTLE, WA / ACCESSWIRE / September 18, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary...
► Artikel lesen
17.09.Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules402SEATTLE, WA / ACCESSWIRE / September 16, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary...
► Artikel lesen
16.09.Aptevo und Alligator berichten über vielversprechende Studienergebnisse für Krebsmedikament1
16.09.Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study189Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor TypesProlonged stable disease lasting >11 months demonstrated in Breast Cancer PatientFavorable Pharmacokinetics, Safety and...
► Artikel lesen
16.09.Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study233Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor TypesProlonged stable disease lasting >11 months demonstrated in Breast Cancer PatientFavorable Pharmacokinetics, Safety and...
► Artikel lesen
Seite:  Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1